US Patent Issued to Numab Therapeutics on Dec. 23 for "Multispecific antibodies having specificity for TNFAlpha and IL-17A, antibodies targeting IL-17A, and methods of use thereof" (Swiss Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,505, issued on Dec. 23, was assigned to Numab Therapeutics AG (Horgen, Switzerland).

"Multispecific antibodies having specificity for TNFAlpha and IL-17A, antibodies targeting IL-17A, and methods of use thereof" was invented by David Urech (Jona, Switzerland), Tea Gunde (Zurich), Sebastian Meyer (Eggenwil, Switzerland) and Christian Hess (Zurich).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an isolated multispecific antibody comprising a first domain specifically binding TNFAlpha and a second domain specifically binding IL-17A and, optionally, a third domain specifically binding human serum albumin. The present inve...